3Burr ML, Viatte S, Bukhari M,et al. Long - term sta- bility of anti - cyclic citrullinated peptide antibody sta- tus in patients with early inflammatory polyarthritis [ J ]. Arthritis Rheum and therpy, 2012, 14 ( 3 ) : 1186 - 1196.
4Iuliia B, Tanja AS, Jose MA, et al. Application of the 2010 ACR/EULAR classification criteria in patients with very early inflammatory arthritis : analysis of sensi- tivity, specificity and predictive values in the save study cohort [ J ]. Annals of the Rheumatic Diseases, 2013,72(8) : 1335 - 1341.
5Sun J, Zhang Y, Liu L, et al. Diagnostic accuracy of combined tests of anti - cyclic citrullinated peptide an- tibody and rheumatoid factor for rheumatoid arthritis:a meta - analysis [ J ]. Clin Exp Rheumatol, 2014, 32 (1) :11 -21.
6Shakiba Y, Koopah S, Jamshidi AR, et al. Anti - cy- clic citrullinated Peptide antibody and rheumatoid fac- tor isotypes in Iranian patients with rheumatoid arthri- tis: evaluation of clinical value and association with disease activity [ J ]. Iran J Allergy Asthma Immunol, 2014 ,13(3) :147 - 156.
7Hiura K, Iwaki - Egawa S, Kawashima T, et al. The diagnostic utility of matrix metailoproteinase - 3 and high - sensitivity C - reactive protein for predicting rheumatoid arthritis in anti - cyclic citrullinated pep- tide antibody - negative patients with recent - onset undifferentiated arthritis [ J ]. Rheumatology Interna- tional,2013, 33 (9) :2309 - 2314.
